Bracket forms new SAB subcommittee

New entity focused on Alzheimer’s disease holds inaugural meeting at CTAD 2016
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
WAYNE, Pa.—Bracket, a clinical trial technology and specialty services provider with expertise in Alzheimer’s disease (AD), announced recently that its scientific advisory board (SAB) had formed an AD subcommittee—with the SAB deciding to hold that AD entity’s inaugural meeting at the Ninth Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference in December of last year in San Diego.
 
The subcommittee, chaired by and established in collaboration with Dr. Jeffrey Cummings, director of Cleveland Clinic’s Lou Ruvo Center for Brain Health and Camille, and Larry Ruvo, chair of the Neurological Institute of Cleveland Clinic, will focus exclusively on maintaining Bracket’s awareness and involvement in AD research advancement, field changes, emerging technologies and competitive landscape.
 
As a specialty services provider with specific expertise in AD trial technology, including the development and launch of Bracket eCOA, Bracket’s subcommittee will build upon the company’s strategic agenda to capture data using technology, finding innovative ways to minimize error-prone human factors in clinical trials. The committee will be critical in assessing the acceptability of new technologies to sites.
 
“Bracket’s SAB is well-represented across various therapeutic areas, but we maintain a specialized focus on AD in effort to combat the many challenges facing its clinical trials today,” said Jeff Kinell, CEO of Bracket. “We’ve invested tremendously on improving outcomes in the area and we’re hopeful that this focused subcommittee will connect the right data, minds and initiatives to move AD trials forward.”
 
With plans to meet several times per year at relevant meetings such as the American Academy of Neurology Annual Meeting and Alzheimer’s Association International Conference, the committee will share meeting notes and coordinate on common projects with Bracket’s SAB, while operating independently.
 
Also in early 2017 news from the company, Bracket announced the addition of Jennifer Peters to its growing team as the company’s new senior vice president and general manager for the Scientific Services division. In this role, she will be responsible for Bracket’s work in rater training, quality assurance and electronic clinical outcomes assessments. Peters joins Bracket with a strong skill set and demonstrated record building technology-based businesses in life sciences.
 
She has more than 14 years of life-sciences industry experience, most recently serving as a founder and chief experience officer of Greenphire, a global provider of disruptive clinical trials payment and process optimization technology products serving pharmaceutical sponsors, biotech companies and CROs. She led Greenphire from an idea-stage startup, with three founding employees at its inception in October 2007, to a global technology enterprise with more than 100 employees and over 500 clients when it was sold to a private equity firm in 2014.

Related Topics

Published In

Volume 13 - Issue 3 | March 2017

March 2017

March 2017 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Image Alt Text	A laboratorian wearing blue gloves places a PCR sample into a real-time PCR thermocycler, the model shown is blue and white with a large digital screen.
From primer design to sample preparation, explore comprehensive strategies to optimize PCR throughput and reproducibility.
Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue